Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
30,780,072
-
Share change
-
+1,342,105
-
Total reported value
-
$305,983,391
-
Put/Call ratio
-
73%
-
Price per share
-
$9.94
-
Number of holders
-
93
-
Value change
-
+$11,819,146
-
Number of buys
-
47
-
Number of sells
-
47
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2022
As of 31 Mar 2022,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
93 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,780,072 shares.
The largest 10 holders included
PICTET ASSET MANAGEMENT SA, BlackRock Inc., VANGUARD GROUP INC, HHLR ADVISORS, LTD., BAKER BROS. ADVISORS LP, ArrowMark Colorado Holdings LLC, Hudson Bay Capital Management LP, GREAT POINT PARTNERS LLC, Opaleye Management Inc., and MILLENNIUM MANAGEMENT LLC.
This page lists
93
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.